Αρχική World News Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage... World News Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC Από Ogkologos - 17 Σεπτεμβρίου, 2026 140 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a second planned interim analysis of the AEGEAN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer 7 Μαΐου, 2021 The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... 20 Δεκεμβρίου, 2018 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... 26 Μαΐου, 2023 Overall Survival Significantly Longer with Darolutamide in Non-metastatic CRPC 14 Σεπτεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Children’s cancer charities team up for tomorrow’s treatments EU Cancer Mission and Partners Launch First Cancer Mission Forum for... 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. Giving Myself the Most Time and Best Chance at Beating Cancer:...